• About us
• Contact

Advertisement

Organisation › Details

CRISPR Therapeutics (Group)

CRISPR Therapeutics is a leading gene-editing company focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The Company’s multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the Company’s scientific founder Emmanuelle Charpentier, Ph.D., who co-invented the application of CRISPR/Cas9 for gene editing. CRISPR Therapeutics is headquartered in Basel, Switzerland with its R&D operations based in Cambridge, Massachusetts. *

 

	Start	2013-01-01 established
	Industry	CRISPR gene editing technology
	Person	Kulkarni, Samarth (Sam) (CRISPR Therapeutics 201712– promoted CEO before CBO)
	Person 2	Prasad, Raju (CRISPR Therapeutics 202303– CFO before William Blair)
	Region	Basel BS
	Country	Switzerland
	Street	36 Aeschenvorstadt
	City	4051 Basel
		Address record changed: 2020-12-02
Basic data	Employees	D: 101 to 500 (2023-12-31)
	Currency	USD
	Annual sales	371,206,000 (revenue, total, consolidated (2023) 2023-12-31)
	Profit	-153,610,000 (2023-12-31)
	Cash	1,693,692,000 (2023-12-31)
		* Document for »About Section«:
		Record changed: 2024-05-29

Advertisement

More documents for CRISPR Therapeutics (Group)

• [1] CRISPR Therapeutics AG. (3/13/24). "Press Release: CRISPR Therapeutics Proposes New Appointment to the Board of Directors". Zug & Boston, MA....
• [2] CRISPR Therapeutics AG. (2/13/24). "Press Release: European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, Casgevy (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)". Z...
• [3] CRISPR Therapeutics AG. (2/13/24). "Press Release: CRISPR Therapeutics Announces $280 Million Registered Direct Offering". Zug & Boston, MA....
• [4] CRISPR Therapeutics AG. (1/3/24). "Press Release: CRISPR Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference". Zug & Boston, MA....
• [5] CRISPR Therapeutics AG. (6/13/23). "Pressemitteilung: CRISPR Therapeutics to Participate in Goldman Sachs 44th Annual Global Healthcare Conference". Zug & Cambridge, MA....
• [6] CRISPR Therapeutics AG. (4/13/23). "Press Release: CRISPR Therapeutics to Participate in Needham’s 22nd Annual Healthcare Conference". Zug & Cambridge, MA....
• [7] CRISPR Therapeutics AG. (4/3/23). "Press Release: CRISPR Therapeutics and Vertex Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for Exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalas...
• [8] CRISPR Therapeutics AG. (3/29/23). "Press Release: CRISPR Therapeutics Announces Departure of Board Member". Zug & Boston, MA....
• [9] CRISPR Therapeutics AG. (3/27/23). "Press Release: CRISPR Therapeutics and Vertex Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes". Boston, MA & Zug....
• [10] CRISPR Therapeutics AG. (3/13/23). "Press Release: CRISPR Therapeutics Announces Transition of Chief Financial Officer". Zug & Boston, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.